Conclusions & Recommendations
15.6.1 - Ethiopia - Somali
Conclusion/Recommendation:
TEC commends the FMoH and Regional Health Bureau for identifying funding to treat trachoma in the Somali Region.
Action:
RHB & FMOH have allocated budget for 2016 intervention in four districts with TF >30% to meet 5-year intervention in 2020. Three of the districts have conducted the delayed 2016 distribution and one of them is pending. Furthermore, FMOH has determined to continue with funding in 2018 for all districts with TF ≥10% in Somali region in the absence of a funding partner.
TEC 15
2016
Africa - East
Ethiopia
funding
15.7.1 - Tanzania
Conclusion/Recommendation:
TEC recommends that ITI invite the Tanzanian trachoma program to submit a concept note for operational research to better understand and address the issue of persistent TF in Chamwino and Manyoni. This could include a study to understand the effects of pastoralist communities and the prospects of applying innovative approaches to address them.
Action:
The concept note to conduct operational research was discussed at Tanzania’s TAP workshop in March 2017. They plan to submit a request funding for operational research to better understand the issue of persistent TF
TEC 15
2016
Africa - East
Tanzania
research, persistence, special populations, recommendations for ITI management
15.8.1 - Viet Nam
Conclusion/Recommendation:
TEC approved the Zithromax® request for one round of MDA in the commune of Lung Ho (2,135 treatments).
Action:
This decision has been communicated to Vietnam and partners
TEC 15
2016
South East Asia
Viet Nam
Zithromax® donation criteria
15.8.2 - Viet Nam
Conclusion/Recommendation:
TEC notes that the identification of active trachoma and ocular Chlamydia infection in a single cluster is to be expected and reassures the MOH that this should not compromise the elimination goals.
Action:
This decision has been communicated to Vietnam and partners
TEC 15
2016
South East Asia
Viet Nam
end game
14.1.1 - General Recommendations to ITI
Conclusion/Recommendation:
ITI program team are requested to provide periodic country program updates to their TEC liaisons and are specifically encouraged to reach out to the liaison if there are programmatic challenges where TEC feedback would be of use.
Action:
Adopted and now ongoing
TEC 14
2016
recommendations for ITI management
14.1.2 - General Recommendations to ITI
Conclusion/Recommendation:
ITI supply chain team should increase the frequency of communications to all relevant partners regarding the status of Zithromax® shipments.
Action:
Potential solutions will be addressed in presentations at TEC 15
TEC 14
2016
supply chain, recommendations for ITI management
14.1.3 - General Recommendations to ITI
Conclusion/Recommendation:
ITI data team are requested to assess the difference in impact survey results at >20% and >30% to determine whether the R2 reserve category should be adjusted.
Action:
Potential solutions will be addressed in presentations at TEC 15
TEC 14
2016
recommendations for ITI management, evaluation units, TEC meeting management
14.1.4 - General Recommendations to ITI
Conclusion/Recommendation:
ITI-Ethiopia should include a country highlights page for each Ethiopian Region in the TEC book.
Action:
Adopted and now ongoing
TEC 14
2016
TEC meeting management
14.1.5 - General Recommendations to ITI
Conclusion/Recommendation:
TEC agreed to hold a second year of Impact Reserve (R1) when surveys are due, if necessary; ITI program staff will determine how to represent the current year’s Reserve on the applications.
Action:
Adopted and now ongoing
TEC 14
2016
TEC meeting management, Zithromax® donation criteria
14.1.6 - General Recommendations to ITI
Conclusion/Recommendation:
In the absence of any evidence that the policy has disrupted implementation, TEC recommended that ITI continue shipping 95% of approved Zithromax®.
Action:
Adopted and now ongoing
TEC 14
2016
supply chain, recommendations for ITI management